Chat
von Willebrand Disease, Type 2B (VWF) Sequencing
Copy Utility
Molecular testing to confirm a phenotypic diagnosis of von Willebrand disease type 2B and to distinguish from pseudo (platelet-type) VWD.
Polymerase Chain Reaction/Sequencing
Varies
14-21 days
Lavender (EDTA), pink (K2EDTA) or yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Refrigerated.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
By report
Background Information for von Willebrand Disease, Type 2B (VWF) Sequencing:
Characteristics: Mucocutaneous bleeding after brushing or flossing teeth, unexplained bruising, prolonged repeated nosebleeds, menorrhagia, and prolonged bleeding following childbirth, trauma or surgery.
Incidence: Approximately 1 in 100 to 1 in 1000 individuals.
Inheritance: Autosomal dominant for types 2B, 2M and most of 2A; autosomal recessive for 20 percent of 2A.
Penetrance: Dominant mutations are incompletely penetrant when VWF:Ag and VWF:RCo levels are 25-50 IU/dL. Full penetrance is expected when VWF:Ag and VWF:RCo levels are less than 25 IU/dL.
Cause: Pathogenic VWF mutations in exon 28.
Clinical Sensitivity: 80 percent for vWD types 2A, 2B, and 2M; unknown for other vWD subtypes.
Methodology: Bidirectional sequencing of VWF exon 28 and its intron-exon boundaries.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, deep intronic mutations, and large deletion/duplications will not be detected. Mutations lying outside of VWF exon 28 are not evaluated.
Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
81403
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2005487 | vWD2B (VWF) Specimen | |
| 2005488 | vWD Type 2B (VWF) Sequencing Interp |
- VWD type 2B sequencing assay
- VWF2B Sequencing
Feedback
